Ann: Inflammatory Lung Disease Outcomes For Presentation at ISCT, page-64

So correct me if I am wrong, but essentially people with severe COVID-19 die from ARDS (acute respiratory distress syndrome). Diseases such as covid-19 and influenza can be fatal due to an overreaction of the body’s immune system called a cytokine storm. Cytokines (small proteins) are released by the immune system. The body’s response to infection goes into overdrive. When COVID-19 enters the lungs, it triggers an immune response, attracting immune cells to the region to attack the virus, resulting in localised inflammation. Excessive or uncontrolled levels of cytokines are released which then activate more immune cells, resulting in hyper-inflammation. This is the infection that literally sits on your alveolus (tiny membranes at the end of your lungs that pass oxygen into your bloodstream) literally drowning patients as they cannot get oxygen through to the bloodstream as their alveolus are massively inflamed impeding the transfer. People get no oxygen to their bloodstream, hence the drowning analogies.

So via the company's explanation Remestemcel-L (stem cell based) which was developed for various inflammatory conditions, to counteract the inflammatory processes implicated in these diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues. Remestemcel-L intravenous infusions have been evaluated in over 1,100 patients in various clinical trials mainly in relation to acute graft versus host disease (aGVHD) in children, a potentially fatal inflammatory condition due to a similar cytokine storm process as is seen in COVID-19 ARDS. Additionally, a post-hoc analysis of a randomized, placebo-controlled study in 60 patients with chronic obstructive pulmonary disease demonstrated that remestemcel-L significantly improved respiratory function in patients with the same elevated inflammatory bio-markers that are also observed in patients with COVID-19 ARDS.

I know the FDA has granted trials and it had a decent run-up but how the hell has MSB fallen to the sidelines. Unlike any other treatment out there, it literally attacks the very cytokine storm that causes death? Other treatments sound hashed by comparison. I like Ivermectin in at least it is tackling the viruses ability to get into the nucleus of our cells and therefore disrupt our anti-viral response which allows the virus to multiply. But Remestemcel-L literally counteracts and down regulates the cytokine storm. How this is not be lauded as a treatment compared to the crap out there....

Anyone have a timeline on trials?